Sign in Subscribe
Cancer research

Pembrolizumab and Lenvatinib Show Favorable Clinical Benefit in Recurrent Ovarian Cancer

Strategic Insights

— 1 min read

Researchers at the University of Texas MD Anderson Cancer Center have found that the combination of pembrolizumab and lenvatinib demonstrates favorable clinical benefit in recurrent, platinum resistant microsatellite stable (MSS)/mismatch repair proficient (pMMR) ovarian cancer. This study adds to the growing body of evidence supporting the use of immunotherapy in ovarian cancer. According to the study, 54% of patients who received pembrolizumab and lenvatinib had a partial response, and 31% had stable disease, with a 6-month clinical benefit rate of 69%. The median progression-free survival for all evaluable patients was 7.9 months.

Key Takeaways:

  • The combination of pembrolizumab and lenvatinib has shown favorable clinical benefit in recurrent, platinum resistant MSS/pMMR ovarian cancer.
  • 54% of patients who received pembrolizumab and lenvatinib had a partial response.
  • 31% of patients who received pembrolizumab and lenvatinib had stable disease.
  • The 6-month clinical benefit rate was 69%.
  • The median progression-free survival for all evaluable patients was 7.9 months.
  • The study was a retrospective cohort study of 16 patients who received pembrolizumab and lenvatinib at the MD Anderson Cancer Center at Cooper.
  • The majority of patients (93.75%) had FIGO stage III/IV disease.
  • 80.1% of patients had platinum-resistant recurrent disease.

Statistics:

  • 54% of patients had a partial response to pembrolizumab and lenvatinib.
  • 31% of patients had stable disease to pembrolizumab and lenvatinib.
  • The 6-month clinical benefit rate was 69%.
  • 7.9 months was the median progression-free survival for all evaluable patients.
  • 80.1% of patients had platinum-resistant recurrent disease.
  • 93.75% of patients had FIGO stage III/IV disease.
  • 16 patients were included in the study.

Sources:

  • Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience. Gynecologic Oncology Reports, 2025, 60():101811 (http://www.journals.elsevier.com/gynecologic-oncology-reports/)
  • NewsRx. Study Findings from University of Texas MD Anderson Cancer Center Update Knowledge in Ovarian Cancer (Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience). OBGYN & Reproduction Week. September 8, 2025; p 617.

Read more